Horizon Kinetics Asset Management LLC Boosts Holdings in Amgen Inc. (NASDAQ:AMGN)

Horizon Kinetics Asset Management LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,597 shares of the medical research company’s stock after buying an additional 141 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Amgen were worth $938,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. 1ST Source Bank increased its stake in shares of Amgen by 4.0% in the fourth quarter. 1ST Source Bank now owns 2,988 shares of the medical research company’s stock worth $779,000 after purchasing an additional 116 shares in the last quarter. Cibc World Markets Corp increased its stake in shares of Amgen by 3.8% in the fourth quarter. Cibc World Markets Corp now owns 238,112 shares of the medical research company’s stock worth $62,062,000 after purchasing an additional 8,811 shares in the last quarter. Creative Financial Designs Inc. ADV increased its stake in shares of Amgen by 2.9% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 5,300 shares of the medical research company’s stock worth $1,381,000 after purchasing an additional 151 shares in the last quarter. Robinson Smith Wealth Advisors LLC increased its stake in shares of Amgen by 8.8% in the fourth quarter. Robinson Smith Wealth Advisors LLC now owns 805 shares of the medical research company’s stock worth $210,000 after purchasing an additional 65 shares in the last quarter. Finally, Signature Wealth Management Group increased its stake in shares of Amgen by 126.2% in the fourth quarter. Signature Wealth Management Group now owns 1,796 shares of the medical research company’s stock worth $468,000 after purchasing an additional 1,002 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 1.1 %

Shares of AMGN opened at $317.17 on Tuesday. The firm has a market cap of $170.39 billion, a price-to-earnings ratio of 42.01, a PEG ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm has a 50 day moving average price of $292.99 and a 200-day moving average price of $299.02.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.00%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s payout ratio is 126.09%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on AMGN shares. Redburn Partners reduced their price objective on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. UBS Group reaffirmed a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Johnson Rice set a $294.00 price objective on shares of Amgen in a research note on Wednesday, March 5th. Finally, Piper Sandler boosted their price objective on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $314.04.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 over the last three months. 0.69% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.